A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Latest Information Update: 02 Aug 2023
At a glance
- Drugs Atezolizumab (Primary) ; Tocilizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Jul 2023 Status changed from not yet recruiting to recruiting.
- 10 Apr 2023 Planned End Date changed from 1 Apr 2026 to 1 Sep 2026.
- 10 Apr 2023 Planned primary completion date changed from 1 Jul 2025 to 1 Dec 2025.